Skip to main content
Akero Therapeutics, Inc. logo

Akero Therapeutics, Inc. — Investor Relations & Filings

Ticker · AKRO ISIN · US00973Y1082 LEI · 549300SI3KG74LBE2955 US Professional, scientific and technical activities
Open in API
Filings indexed 719 across all filing types
Latest filing 2022-09-14 Director's Dealing
Country US United States of America
Listing US AKRO

About Akero Therapeutics, Inc.

https://akerotx.com/

Akero Therapeutics, Inc. is a clinical-stage company focused on developing and commercializing transformational treatments for patients with serious metabolic diseases characterized by high unmet medical need. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 (FGF21). EFX is being evaluated in multiple clinical trials as a potential foundational therapy for metabolic dysfunction-associated steatohepatitis (MASH), a severe form of liver disease. The program aims to provide a differentiated treatment that addresses the complex pathophysiology of MASH by restoring metabolic balance.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2022-09-14 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a preliminary prospectus supplement filed pursuant to Rule 424(b)(5) related to a registration statement for a public offering of common stock. It includes detailed information about the offering, underwriting, risk factors, company overview, and use of proceeds. This type of document is a capital markets filing related to fundraising and issuance of securities, not a financial report, earnings release, or management discussion. It is not an announcement of a report but the actual offering document. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed offering terms, consistent with a CAP filing.
2022-09-13 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events or updates that shareholders should know about. The text includes a press release about clinical trial results and a slide presentation, both furnished as exhibits. There are no detailed financial statements or comprehensive financial analysis typical of annual or quarterly reports. The document primarily serves to disclose recent material events and provide regulatory disclosure rather than detailed financial data or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2022-09-13 English
10-Q
Interim / Quarterly Report Q2 2022
2022-08-05 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 4, 2022, reporting the financial results for the quarter ended June 30, 2022. It specifically states that a press release with the financial results is furnished as an exhibit. The text does not contain the actual financial statements or detailed financial data but rather announces the results and provides a press release. The document length is 3471 characters, which is relatively short and consistent with an earnings release announcement rather than a full report. According to the rules, initial announcements of quarterly financial results with key highlights only are classified as Earnings Release (ER).
2022-08-04 English
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC by Akero Therapeutics, Inc. dated June 15, 2022. It reports entry into a material definitive agreement including a securities purchase agreement and a loan and security agreement, detailing financing transactions with Pfizer Inc. and Hercules Capital, Inc. The document includes detailed terms of the financing agreements, loan tranches, interest rates, repayment terms, and warrants issued. It also references a press release about the financing transactions. The content is focused on financing activities and capital structure changes, not on earnings, management changes, or other report types. The document length is over 14,000 characters and contains substantive details about the financing agreements, not just an announcement or summary. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2022-06-16 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.